NCT07154355 Community Exercise Treating Effect on Cardiopulmonary Disease Patients
| NCT ID | NCT07154355 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | Coronary Heart Disease (CHD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-01-30 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-01-30 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if community-based exercise training can benefit patients aged 18 to 85 with diminished cardiovascular and pulmonary function. The main aim of this study is: • Establish a community or home-based fitness training program for patients with cardiopulmonary insufficiency to improve adherence, safety, and efficacy while alleviating the burden on both patients and society. Researchers will compare community-based exercise training to non-exercise training to see if community-based exercise training works to improve cardiovascular and pulmonary function. Participants will: * Engage in community or home exercise training for 40-60 minutes, five times weekly, during a duration of eight weeks. Exercise modalities are primarily determined by the patients' individual preferences and habits, such as brisk walking, running, swimming, cycling, and hiking. * Adjust the exercise intensity according to their cardiopulmonary exercise test and the person's perceived exertion level. * Utilize fitness bracelets or watches to document statistics during workouts and submit them to the experimenter weekly, covering the five days of exercise within that week. * refrain from making any dietary modifications throughout the trial.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 to 85 with abnormal pulmonary or cardiovascular function. 2. Individuals who have completed a medical screening form to confirm they are free from illnesses and prescription medications that could impair their ability to complete the required testing and fitness training. 3. Participants who did not engage in structured, systematic moderate-to-intense strength or endurance training during the study period (specifically, not within the previous year). 4. At the onset of the trial, participants were physically active but had never participated in formal exercise more than twice a week. Exclusion Criteria: 1. Patients with neuromuscular or skeletal disorders, or systemic diseases such as diabetes, cancer, or heart disease. 2. Individuals using medications known to affect health or the interpretation of study results. 3. Participants who have engaged in organized, systematic endurance or strength training of moderate to high intensity within the past year. 4. Patients who decline to participate in the study. 5. Other medical conditions or states that render exercise training inappropriate.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07154355 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Coronary Heart Disease (CHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07154355 currently recruiting?
Yes, NCT07154355 is actively recruiting participants. Contact the research team at zengbin@gdph.org.cn for enrollment information.
Where is the NCT07154355 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07154355 clinical trial?
NCT07154355 is sponsored by Guangdong Provincial People's Hospital. The trial plans to enroll 200 participants.